(RTTNews) - Hanmi Pharm. Co., Ltd. (128940.KS), a South Korean biopharmaceutical and manufacturing company, on Tuesday reported a decline in net income despite higher sales in the third quarter of 2026 compared with the previous year.
We show the main point publicly. Create a free account to continue reading the full article, save it, discuss it, and connect it with market and OSINT context.